Hodgkin lymphoma (ICD10 C81): combined sexes
Five-year relative survival by diagnosis year and age at diagnosis
|
Five-year relative survival (with 95% confidence interval) by diagnosis year |
EUROCARE-4 |
EUROCARE-4 |
||||||||||
|
Age at diagnosis |
1994-97 |
1998-2002 |
2003-2007 |
2007-2009 |
##2000-2002 |
##2000-2002 |
||||||
|
cohort |
cohort |
cohort |
*hybrid |
Ireland |
Europe average |
|||||||
|
all 15-99 |
78.6% |
81.2% |
87.5% |
88.3% |
||||||||
|
(unstandardized) |
(72.9-83.3%) |
(76.6-85.0%) |
(83.2-91.0%) |
(83.4-92.1%) |
||||||||
|
all 15-99 |
72.1% |
75.4% |
84.1% |
84.3% |
77.2% |
81.4% |
||||||
|
(age-standardized)# |
(72.0-82.7%) |
(78.9-84.1%) |
||||||||||
|
15-44 |
88.3% |
93.1% |
96.1% |
96.9% |
||||||||
|
(82.8-92.1%) |
(89.2-95.7%) |
(92.4-98.1%) |
(92.4-98.8%) |
|||||||||
|
45-54 |
67.5% |
80.3% |
80.2% |
80.6% |
||||||||
|
(46.3-82.1%) |
(66.6-89.1%) |
(63.2-90.1%) |
(57.4-92.2%) |
|||||||||
|
55-64 |
63.5% |
49.6% |
79.3% |
80.2% |
||||||||
|
(43.0-78.7%) |
(31.6-65.6%) |
(62.9-90.7%) |
(61.2-91.2%) |
|||||||||
|
65-74 |
40.4% |
35.6% |
67.0% |
65.2% |
||||||||
|
(21.4-59.5%) |
(20.0-52.3%) |
(49.3-80.2%) |
(43.8-80.8%) |
|||||||||
|
75-99 |
19.7% |
29.9% |
38.2% |
35.6% |
||||||||
|
(3.3-51.6%) |
(10.9-55.2%) |
(18.6-60.3%) |
(14.6-59.4%) |
|||||||||
|
Footnotes: |
|
|
*Hybrid estimate for 2007-2009 is the most up-to-date survival estimate and is based on follow-up of all cases alive at any point during this period, |
|
|
supplemented by follow-up 2005-2009 for cases diagnosed in 2005-2006 (to provide more reliable estimation of the first two years of survival). |
|
|
In practice, the hybrid estimate for 2007-2009 is similar to the most recent (incomplete) cohort, i.e. cases diagnosed 2003-2007, reflecting substantial overlap of data. |
|
|
# Age-standardized figures use the standard patient population proposed for this cancer by: |
|
|
Corazziari I., Quinn M. & Capocaccia R. 2004. Standard cancer patient population for age standardising survival ratios. Eur J Cancer 40: 2307-2316. |
|
|
(Population weights = age 15-44 x28000, 45-54 x17000, 55-64 x21000, 65-74 x20000, 75-99 x14000) |
|
|
## For comparison, the age-standardized average survival (2000-2002) is quoted for countries (including Ireland) that participated in the EUROCARE-4 study: |
|
|
Verdecchia A., Francisci S., Brenner H., et al. 2007. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 8: 784-796. |
|
|
Exclusions (as in EUROCARE): |
|
|
Patients aged <15 or >99 at diagnosis; death-certificate-only (DCO) and autopsy-only cases; second or subsequent malignancies in the same patient |
|
|
(or the less serious of two or more synchronously-diagnosed malignancies); in situ carcinomas and tumours of uncertain behaviour. |
|
|
© National Cancer Registry Ireland 2011 (October 2011) Relative survival statistics for Irish cancer patients |
|